Manager Noam Kirson Presents Research on Misdiagnosis of Alzheimer’s Disease at AAIC 2013
July 17, 2013
Research conducted by a team from Analysis Group and Eli Lilly and Company on the economic impact of Alzheimer's disease misdiagnosis was presented at the Alzheimer's Association International Conference (AAIC) in Boston, Massachusetts, on July 17, 2013. Analysis Group Manager Noam Kirson presented "Excess Costs Associated with Misdiagnosis of Alzheimer's Disease among U.S. Medicare Beneficiaries with Vascular Dementia or Parkinson's Disease" during the conference's developing topics plenary session. The research was funded by Eli Lilly, and examined how the misdiagnosis of Alzheimer's disease in Medicare patients who actually have vascular dementia or Parkinson's disease leads to substantial excess costs of care.
"Recent developments in technology have greatly improved our ability to properly diagnose patients with cognitive impairment," Dr. Kirson commented in an AAIC press release. "Our results suggest that there are economic benefits to properly diagnosing -- as early as possible -- the cause of the cognitive impairment among patients with vascular dementia and Parkinson's disease." Dr. Kirson's research was also featured in a recent CNN article on the early diagnosis of Alzheimer's disease.
Read the press release
Read the CNN article